Examkin

Question

Difficulty: Very hardPharmacologic Interventions

A 52-year-old woman is admitted to the medical intensive care unit due to acute hypoxemic respiratory failure and fever. She underwent a deceased-donor renal allograft transplantation 6 months ago. Her home medications include tacrolimus, mycophenolate mofetil, and prednisone. Temperature is 38.6°C (101.5°F), blood pressure is 118/74 mmHg, heart rate is 106/min, and oxygen saturation is 91% on a high-flow nasal cannula. Laboratory evaluation reveals a serum creatinine of 1.6 mg/dL (up from a baseline of 1.1 mg/dL) and a markedly elevated serum galactomannan antigen. High-resolution computed tomography of the chest demonstrates bilateral macronodular opacities surrounded by ground-glass attenuation (halo sign). Electrocardiography shows normal sinus rhythm with a QTc interval of 430 ms. The interdisciplinary team is formulating the definitive pharmacologic treatment plan.

Which of the following pharmacologic interventions should be implemented simultaneously? (Select all that apply)

  1. Initiate intravenous voriconazoleAnswer
  2. Preemptively reduce the dosage of tacrolimusAnswer
  3. C
    Administer intravenous amphotericin B deoxycholate
  4. D
    Add oral rifampin for broad-spectrum synergistic coverage
  5. E
    Prescribe scheduled intravenous ketorolac for pleuritic pain

Answer

The immediate pharmacologic management requires initiating intravenous voriconazole for invasive aspergillosis and simultaneously preemptively reducing the tacrolimus dosage to prevent severe toxicity due to CYP3A4 inhibition.
The correct interventions address both the primary infectious pathology and the iatrogenic risk created by its treatment. First-line therapy for invasive pulmonary aspergillosis (indicated by the halo sign and positive galactomannan) is voriconazole. However, voriconazole is a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) enzyme. Tacrolimus, a calcineurin inhibitor essential for preventing allograft rejection, is extensively metabolized by CYP3A4. Concomitant administration without dose adjustment leads to a rapid, toxic accumulation of tacrolimus. Therefore, initiating voriconazole must be paired immediately with a preemptive reduction in the tacrolimus dosage (often by one-third to one-half) to prevent acute nephrotoxicity.

Step-by-Step Solution

1
Identify the underlying infectious etiology.
Invasive pulmonary aspergillosis is diagnosed based on the classic 'halo sign' on CT imaging and positive serum galactomannan in a severely immunocompromised host.
Establishing the precise opportunistic pathogen is required to select the targeted antimicrobial therapy.
2
Select the optimal targeted antimicrobial intervention.
Intravenous voriconazole is chosen as the gold-standard primary therapy.
Clinical guidelines dictate voriconazole as the first-line agent for invasive aspergillosis over alternatives due to superior survival outcomes.
3
Analyze the patient's existing medication list for critical drug-drug interactions.
A severe interaction is identified between the new agent (voriconazole) and the patient's baseline immunosuppressant (tacrolimus).
Transplant recipients are highly susceptible to iatrogenic harm from polypharmacy; voriconazole is a profound inhibitor of CYP3A4, the primary metabolic pathway for tacrolimus.
4
Formulate a concurrent pharmacologic mitigation strategy.
The tacrolimus dose is preemptively reduced, and plans for close trough-level monitoring are established.
Failure to reduce the dose would result in toxic tacrolimus levels, culminating in profound acute nephrotoxicity and neurotoxicity.

Key Concept

The management of invasive pulmonary aspergillosis in solid organ transplant recipients requires the initiation of a targeted triazole antifungal (e.g., voriconazole) coupled with the preemptive dose reduction of calcineurin inhibitors (e.g., tacrolimus) to prevent profound toxicity driven by CYP3A4 inhibition.
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic